Chief Business & Financial Officer · Ovid Therapeutics Inc. (OVID)

Jeffrey Rona

A named executive officer of Ovid Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$969,164

Salary $506,892Stock awards $24,806

FY2024: $1,518,796

3rd of 3 named executive officers at Ovid Therapeutics by FY2025 total.

3 named officers on file for Ovid Therapeutics, FY2025

Jeffrey Rona’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Ovid Therapeutics’s whole pay program stands against its peers

  • Ovid Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OVID→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A).

Free

Get Jeffrey Rona’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jeffrey Rona compensation by year

Ovid Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Ovid Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024FY2025
Salary$107,860$455,000$473,200$492,128$492,128$506,892
Bonus$0—$0$0$0$0
Stock awards$0—$0$0$103,500$24,806
Option awards$1,710,293$320,590$923,088$322,735$703,068$118,466
Non-equity incentive$170,000$158,182$189,280$255,907$206,300$305,000
Pension and deferred compensation$0—$0$0$0$0
All other$922—$23,800$13,200$13,800$14,000
Total$1,989,075$937,463$1,609,368$1,083,970$1,518,796$969,164

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ovid Therapeutics Inc. DEF 14A filed April 27, 2026, accession 0001628280-26-027621, and prior-year filings.

How this page was built: the Ovid Therapeutics Inc. filed document, accession 0001628280-26-027621. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

$2.0M
$937K
$1.6M
$1.1M
$1.5M
$969K
FY20
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU43,750$71,312—
RSU18,750$30,562—
Option315,000—$1.05
Option168,750—$3.68
Option12,500—$4.42
Option59,245—$2.72
Option91,146—$2.50
Option262,500—$0.57

Per the Outstanding Equity Awards at Fiscal Year-End table in Ovid Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Ovid Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Jeremy LevinExecutive Chairman and Former Chief Executive Officer$1,934,699
Margaret AlexanderPresident and Chief Executive Officer and Former Chief Operating Officer$1,022,272
Jeffrey Rona · this pageChief Business & Financial Officer$969,164

The full Ovid Therapeutics compensation record

free company brief

This page is one person within Ovid Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ovid Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeffrey Rona's compensation dossier · One-time report. No refunds.